| Name | Title | Contact Details |
|---|
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions.
Wake Researchs network of high-quality research sites and millions of patients is built on decades of experience meeting the needs of sponsors & CROs.
SFBC New Drug Services is a Kennett Square, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AzoRx, Inc. is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.